USPTO 2015–2025 USPTO PatentsView US Corporation

OVID Therapeutics Inc.

USPTO PatentsView assignee record — 51 granted patents across 4 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).

51
Total patents granted
4
CPC technology areas
15.5
Avg claims per patent
+43%
5-year filing velocity

The verdict

OVID holds 51 US patents across 4 technology areas — rank #6,577 of 50,000 tracked assignees.

#6,577
of 50,000 US assignees by volume
Top 53%
by Innovation Score (34.3/100)
15.5
avg claims per patent
+43%
filing velocity, last 5 yrs

Portfolio overview

OVID THERAPEUTICS INC. has been granted 51 US utility patents between 2016 and 2025, placing OVID THERAPEUTICS INC. at rank #6,577 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.5 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a US Corporation, OVID THERAPEUTICS INC. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 34.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 30 grants, compared with 21 in the 2015–2019 window — a +43% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. OVID THERAPEUTICS INC.'s 15.5 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark OVID THERAPEUTICS INC. against peers pursuing similar technology classes.

How does OVID compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows OVID holds 51 patents — placing it at rank #6,577 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

OVID's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

34 Top 53% higher than 47% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

051015 2016201720182019202020212022202320242025 1
USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
OVID THERAPEUTICS INC. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 4 7.8%
2017 6 11.8%
2018 4 7.8%
2019 7 13.7%
2020 11 21.6%
2021 4 7.8%
2022 4 7.8%
2023 5 9.8%
2024 5 9.8%
2025 1 2.0%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Growing

Where it ranks

Overall rank by patents

#6,577

Across all tracked assignees

Innovation Score

34.3 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does OVID THERAPEUTICS INC. hold?
OVID THERAPEUTICS INC. holds 51 US granted patents filed between 2016 and 2025, spanning 4 technology areas.
What is OVID THERAPEUTICS INC.'s Innovation Score?
OVID THERAPEUTICS INC. has an Innovation Score of 34.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does OVID THERAPEUTICS INC. focus on?
OVID THERAPEUTICS INC.'s top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 48 patents. The company has filed patents in 4 CPC subclasses total.
Is OVID THERAPEUTICS INC.'s patent filing rate increasing or decreasing?
OVID THERAPEUTICS INC.'s recent filing velocity is +43% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for OVID THERAPEUTICS INC.'s patents?
OVID THERAPEUTICS INC.'s patents average 15.5 claims each. This falls within the standard range, providing solid legal coverage.
How is the OVID THERAPEUTICS INC. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How to use this portfolio

OVID's 51 grants land it in the top 53% by Innovation Score — but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance — OVID ranks #6,577 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61K — see who else leads that technology area. A61K leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Data sources used on this page
  • USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov